Summary statistics of slopes and turning points for the imatinib mesylate and nilotinib response data
| Slopes and turning points . | Short-term imatinib mesylate . | Long-term imatinib mesylate . | Nilotinib . | |||
|---|---|---|---|---|---|---|
| Mean (SE) . | Median (no. of patients) . | Mean (SE) . | Median (no. of patients) . | Mean (SE) . | Median (no. of patients) . | |
| β1* | −0.0519 (0.0180) | −0.0525 (44) | † | † | −0.0424 (0.0154) | −0.0408 (28) |
| β2* | −0.0041 (0.0061) | −0.0044 (44) | −0.0057 (0.0038) | −0.0042 (14) | −0.0014 (0.0017) | −0.0014 (28) |
| β2 Negative‡ | −0.0064 (0.0038) | −0.0056 (35) | −0.0057 (0.0038) | −0.0042 (14) | −0.0019 (0.0013) | −0.0017 (24) |
| β3* | § | § | −0.0006 (0.0006) | −0.0008 (14) | § | § |
| β3 Negative‡ | § | § | −0.0008 (0.0003) | −0.0008 (13) | § | § |
| τ1, mo* | 4.23 (1.41) | 4.14 (44) | † | † | 4.81 (2.20) | 3.99 (28) |
| τ1 Negative, mo‡ | 4.00 (1.36) | 3.91 (35) | † | † | 4.33 (1.62) | 3.70 (24) |
| τ2,mo* | § | § | 34.5 (22.6) | 28.3 (14) | § | § |
| τ1 Negative, mo‡ | § | § | 29.5 (13.4) | 27.3 (13) | § | § |
| Slopes and turning points . | Short-term imatinib mesylate . | Long-term imatinib mesylate . | Nilotinib . | |||
|---|---|---|---|---|---|---|
| Mean (SE) . | Median (no. of patients) . | Mean (SE) . | Median (no. of patients) . | Mean (SE) . | Median (no. of patients) . | |
| β1* | −0.0519 (0.0180) | −0.0525 (44) | † | † | −0.0424 (0.0154) | −0.0408 (28) |
| β2* | −0.0041 (0.0061) | −0.0044 (44) | −0.0057 (0.0038) | −0.0042 (14) | −0.0014 (0.0017) | −0.0014 (28) |
| β2 Negative‡ | −0.0064 (0.0038) | −0.0056 (35) | −0.0057 (0.0038) | −0.0042 (14) | −0.0019 (0.0013) | −0.0017 (24) |
| β3* | § | § | −0.0006 (0.0006) | −0.0008 (14) | § | § |
| β3 Negative‡ | § | § | −0.0008 (0.0003) | −0.0008 (13) | § | § |
| τ1, mo* | 4.23 (1.41) | 4.14 (44) | † | † | 4.81 (2.20) | 3.99 (28) |
| τ1 Negative, mo‡ | 4.00 (1.36) | 3.91 (35) | † | † | 4.33 (1.62) | 3.70 (24) |
| τ2,mo* | § | § | 34.5 (22.6) | 28.3 (14) | § | § |
| τ1 Negative, mo‡ | § | § | 29.5 (13.4) | 27.3 (13) | § | § |
The table displays the first (β1), second (β2), and third (β3) slopes as well as the first (τ1) and second (τ2) turning points for all patients whose treatment response data displayed a biphasic trend on the basis of the BIC criterion (see supplemental Information), as well as for those whose second and third slopes were negative.
The total number of patients used to calculate mean, median, and SE are given by those who displayed a biphasic trend in their treatment response kinetics (see supplemental Information).
Not observable because of data resolution.
Mean and median are calculated using all individual patients whose response data displayed a biphasic trend on the basis of the BIC criterion and whose data also had negative slopes (see supplemental Information).
Not observable because of insufficient follow-up.